Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II concurrent EP chemotherapy with accelerated 3D conformal thoracic radiotherapy for limited-stage small cell lung cancer
ChiCTR-ONC-13004856Phase 2Completed
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Aug 2007
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etoposide, cisplatin and carboplatin in small cell lung cancer (SCLC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: 2-year progression-free survival. Started Aug 2007; status: completed.
02
Drugs
etoposidecisplatincarboplatin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR-ONC-13004856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONC-13004856.